Related Experiment Video
Updated: Jul 20, 2026

Formulation and Characterization of Bioactive Agent Containing Nanodisks
Published on: March 17, 2023
Toxicity of an effective amphotericin B formulation at high cationic lipid to drug molar ratio
Nilton Lincopan1, Primavera Borelli, Ricardo Fock
1Departamento de Bioquímica, Instituto de Química, Universidade de São Paulo, CP 26077, Avenida Lineu Prestes 748 - Butantã, CEP 05513-970 São Paulo, Brazil.
Abstract:
Therapeutic activity of an effective and less nephrotoxic amphotericin B (AMB) formulation with dioctadecyldimethylammonium bromide (DODAB) bilayer fragments (named DODAB/AMB) inspired this toxicity survey in mice. At low drug to lipid molar ratios, hepatotoxicity, spleen damage and blood changes in comparison to DOC/AMB (sodium desoxycholate/amphotericin B, Fungizone) are evaluated ultimately showing toxic effects associated to DODAB only. Swiss Webster female mice were given DODAB, DODAB/AMB or DOC/AMB intraperitonially (ip) for 10 consecutive days (0.4 mg/kg/day AMB; 80 mg/kg/day DODAB) and repeated dose-toxicity was evaluated at the end of the treatment period (on day 11) and after a recovery period of 6 months from biochemical and hematological parameters plus histopathological examination of spleen and liver. Both at day 11 and 180, DODAB in the formulation administered ip causes irreversible changes in spleen such as fibrosis and leukocytes infiltration as a consequence of the administration route. Whereas focal necrosis is induced by DODAB in liver at day 180, DOC/AMB causes more severe multifocal necrosis both at day 11 and day 180. In the kidneys, the novel formulation preserves integrity of tubules and glomeruli in contrast to the serious damage caused by DOC/AMB as shown previously. The majority of the toxic effects observed for the novel formulation were due to the DODAB carrier used at 10mg/mL, i.e., at a rather high concentration and further studies should minimize DODAB dose.
Insights
The novel DODAB/AMB formulation shows reduced kidney toxicity compared to Fungizone. However, the DODAB carrier caused spleen damage and liver effects, necessitating dose reduction in future studies.
Area of Science:
- Pharmacology
- Toxicology
- Drug Delivery
Background:
- Amphotericin B (AMB) is a vital antifungal, but its nephrotoxicity limits use.
- Novel formulations aim to improve AMB's therapeutic index.
- Dioctadecyldimethylammonium bromide (DODAB) bilayer fragments offer a potential AMB delivery system.
Purpose of the Study:
- To evaluate the toxicity of a DODAB/AMB formulation in mice.
- To compare its toxicity profile with the conventional DOC/AMB (Fungizone).
- To assess long-term effects on spleen, liver, and kidneys.
Main Methods:
- Swiss Webster female mice received intraperitoneal injections of DODAB, DODAB/AMB, or DOC/AMB for 10 days.
- Toxicity assessed via biochemical, hematological, and histopathological analyses on day 11 and after 6 months.
- Specific focus on spleen, liver, and kidney damage.
Main Results:
- DODAB/AMB demonstrated significantly less kidney toxicity than DOC/AMB.
- DODAB administration, even within the formulation, led to irreversible spleen fibrosis and leukocyte infiltration.
- DODAB caused focal liver necrosis at 6 months, while DOC/AMB induced more severe multifocal necrosis earlier and longer.
- Most observed toxicities were attributed to the DODAB carrier at the tested concentration.
Conclusions:
- The DODAB/AMB formulation is less nephrotoxic than DOC/AMB.
- The DODAB carrier is responsible for observed spleen and liver toxicities.
- Future research should focus on minimizing DODAB concentration to mitigate its side effects.
Related Concept Videos
Antifungal Agents
Estimation of k and VD of Aminoglycosides
Inhibitors of Bacterial Protein Synthesis
Formation of Complex Ions
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Drug Toxicity: Dose-Dependent Reactions

